US Patent 4,137,309: Scope, Claims, and Patent Landscape for Geminal Diphosphonates in Sickle Cell Anemia
US Drug Patent 4,137,309 claims a method of treating sickle cell anemia by administering geminal diphosphonate compounds. The claims are written as process claims (method-of-treatment), with compound identity narrowed by dependent claims to specific geminal diphosphonates and salt forms.
What does the patent claim, in plain scope terms?
Core independent claim
Claim 1
- Infringing act: “administering to patients in need” of sickle cell anemia
- Method: “a safe and effective amount”
- Acted-upon material: “a geminal diphosphonate compound”
Claim 1 scope
- Covers any geminal diphosphonate compound that falls within the patent’s definition (as interpreted by the specification and claim construction)
- Is limited by:
- Condition: sickle cell anemia
- Dosage posture: “safe and effective amount”
- Class: geminal diphosphonates (not general phosphonates broadly)
Key dependent claim narrowing
Claim 2 (two-compound genus limitation)
- Geminal diphosphonate is selected from:
- ethane-1-hydroxy-1,1-diphosphonic acid
- pharmaceutically acceptable salts and esters of the above
Claim 3 (salt specificity)
- Compound is specifically the sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid
Claim 4 (broader second genus)
- Geminal diphosphonate is selected from:
- methanediphosphonic acid
- pharmaceutically acceptable salts and esters of the above
Claim 5 (more specific halogenated diphosphonate)
- Geminal diphosphonate is selected from:
- methanedichlorodiphosphonic acid
- pharmaceutically acceptable salts and esters of the above
Net claim structure
- Claim 1: broad “geminal diphosphonate” treatment method
- Claims 2 and 4: narrower compound selections within specific named geminal diphosphonate frameworks
- Claim 3: narrower still (sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid)
- Claim 5: additional narrower named compound (methanedichlorodiphosphonic acid)
How should claim coverage be read for enforcement and design-arounds?
1) The patent is anchored to a therapeutic indication
Because all claims recite “treating sickle cell anemia” and “patients in need,” enforcement typically targets:
- clinical administration in the US for that indication, using the claimed class of geminal diphosphonates
- labels and practice patterns that induce the claimed method, depending on how the product is promoted and used
2) Compound scope is determined by the “geminal diphosphonate” classification
Claim 1 depends on the chemical interpretation of “geminal diphosphonate compound.” In practice, this means:
- Many non-geminal phosphonate frameworks would fall outside
- Compounds with diphosphonate motifs that are “geminal” (both phosphonate groups on the same carbon center) are most likely inside the claim perimeter
3) Dependent claims create multiple “fallback” points
Even if a product argued it does not meet Claim 1’s broad chemistry boundary, it still risks infringement if it matches:
- the ethane-1-hydroxy-1,1-diphosphonic acid family (Claims 2-3)
- methanediphosphonic acid family (Claim 4)
- methanedichlorodiphosphonic acid family (Claim 5)
4) “Pharmaceutically acceptable salts and esters” expands coverage
Claims 2, 4, and 5 extend beyond the named acids to:
- salts (including the specific sodium salt called out in Claim 3)
- esters
This expansion typically matters for formulation, prodrug-like ester delivery, and salt selection.
What is the claim-by-claim infringement map?
Claim-by-claim coverage
| Claim |
What must be satisfied |
Compound limitations |
Practical enforcement posture |
| 1 |
Treat sickle cell anemia by administering safe and effective amount of a geminal diphosphonate |
Any geminal diphosphonate compound as construed |
Broadest independent coverage; hardest for a challenger to avoid if chemistry matches “geminal diphosphonate” |
| 2 |
Same method plus compound selection |
Ethane-1-hydroxy-1,1-diphosphonic acid and pharmaceutically acceptable salts/esters |
Medium scope; direct hit if the API or a prodrug/ester delivering that motif is used |
| 3 |
Same method plus compound selection |
Sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid |
Narrow; direct hit if marketed/used as that salt |
| 4 |
Same method plus compound selection |
Methanediphosphonic acid and pharmaceutically acceptable salts/esters |
Medium scope alternative genus |
| 5 |
Same method plus compound selection |
Methanedichlorodiphosphonic acid and pharmaceutically acceptable salts/esters |
Narrow but chemically distinct from ethane-1-hydroxy route |
What is the patent landscape around US 4,137,309 for this therapeutic area and chemical class?
Landscape structure: two layers of competition
- Indication layer (sickle cell anemia treatment methods)
- The key protected act is administration of geminal diphosphonates to treat sickle cell anemia.
- In the broader sickle cell landscape, many later innovations focus on:
- hemoglobin biology modifiers
- anti-sickling pathways
- gene and cellular therapies
- red cell trait modulation
- Those typically do not rely on geminal diphosphonate compounds, so they do not read naturally onto a geminal diphosphonate method claim.
- Chemistry layer (geminal diphosphonate administration)
- Within this narrower chemistry class, coverage is sensitive to:
- “geminal” structural definition
- exact named geminal diphosphonate scaffolds listed in dependent claims
- salt/ester variants
Where later products would be most likely to collide
A collision probability is highest when a later program:
- uses a geminal diphosphonate scaffold
- seeks sickle cell anemia treatment
- selects salt/ester forms that map to the claim’s listed families
If a later program instead uses different classes of phosphonates (non-geminal) or unrelated small molecules, it typically avoids the chemical claim boundary even if it targets sickle cell anemia.
How do the claims support multiple validity and infringement arguments?
1) Claim construction focuses on “geminal diphosphonate”
- Claim 1 will rise or fall on chemical interpretation of “geminal diphosphonate compound.”
- Dependent claims reduce interpretive ambiguity by anchoring to specific named compounds.
2) Salt and ester coverage increases infringement surface area
- If an accused product uses an ester prodrug form of one of the claimed acids, the “esters thereof” language in Claims 2/4/5 can increase the odds that the administered material falls within claim scope, depending on whether the ester is itself the claimed “compound” versus merely a prodrug converting in vivo.
3) “Safe and effective amount” supports broad dosing capture
- The claim is not tied to a specific mg/kg or regimen. It captures dosing strategies that fall within ordinary therapeutic safety and efficacy ranges for the claimed indication.
What claims are most likely to be commercially relevant?
Highest commercial leverage
- Claim 1 is the principal coverage driver because it is not limited to one or two named molecules; it is a method claim for the full class of geminal diphosphonates.
Fallback positions
- Claims 2-3 provide strong anchoring around ethane-1-hydroxy-1,1-diphosphonic acid, including sodium salt.
- Claims 4-5 protect additional, chemically distinct geminal diphosphonate families.
Design-around logic based on the claim set
To avoid infringement, an entrant would generally need to move either:
- outside the “geminal diphosphonate” class definition, or
- outside the specific listed scaffolds and their salt/ester equivalents, while still achieving a therapeutic effect.
What is the practical freedom-to-operate risk profile from the claim language alone?
US 4,137,309’s risk is:
- Process-method dependent rather than product-use independent
- Chemistry class dependent for Claim 1, and compound specific for Claims 2-5
- Expanded by salt and ester language
That combination increases exposure for programs that:
- repurpose known geminal diphosphonates for sickle cell anemia
- develop new salt/ester formulations around the same acid structures
- run clinical practice or labeling that supports “treating sickle cell anemia” by administering the claimed class
Key Takeaways
- US 4,137,309 is a method-of-treatment patent: it claims administration of geminal diphosphonate compounds to treat sickle cell anemia.
- Claim 1 is broad (any geminal diphosphonate), while Claims 2-5 narrow to specific named geminal diphosphonate acids and their pharmaceutically acceptable salts and esters.
- Salt/ester language widens coverage, increasing infringement risk for formulation and prodrug strategies that map to the listed acids.
- Enforcement and design-around hinge on chemical classification (“geminal diphosphonate”) and on whether the administered compound falls within the named dependent claim scaffolds.
FAQs
1) Does US 4,137,309 protect a specific drug molecule only?
No. Claim 1 covers the method using any geminal diphosphonate compound (as construed). Claims 2-5 narrow to specific named geminal diphosphonate acids and their salts/esters.
2) What limits infringement for Claim 1?
The treatment must be for sickle cell anemia, and the administered agent must be a geminal diphosphonate compound at a safe and effective amount.
3) Are salts covered?
Yes. Claims 2, 4, and 5 explicitly include pharmaceutically acceptable salts, and Claim 3 specifically recites the sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid.
4) Are esters covered?
Yes. Claims 2, 4, and 5 include pharmaceutically acceptable esters of the named acids.
5) How do dependent claims affect risk?
They create multiple compound-based “infringement hooks.” Even if a challenger attacks Claim 1’s breadth, the claim set still captures specific compound families via Claims 2-5.
References
- US Patent 4,137,309 (claims as provided in the prompt).
